1 From the Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin.
Mantle cell lymphoma (MCL) is a heterogenous disease with historically relative poor outcomes. However, new treatment strategies seem to be improving the prognosis for patients. Although no universally accepted standard of care exists, options for patients with newly diagnosed MCL include intensive and nonintensive strategies. Generally, intensive strategies produce more durable remissions and are selected for younger patients, whereas nonintensive strategies are most appropriate for older patients or patients with comorbidities. However, new options are closing the treatment gap between intensive and nonintensive strategies. Treatment options are also increasing for patients with relapsed/refractory MCL and include agents targeting the microenvironment and the B-cell receptor signaling pathway.
Correspondence: Brad S. Kahl, MD, University of Wisconsin School of Medicine, 1111 Highland Avenue, 4059 WIMR, Madison, WI 53705. E-mail: firstname.lastname@example.org